According to World Heart Federation, Nearly 4.4 million people die each year due to complications linked to high cholesterol. Most people think of cholesterol as something “bad,” but its not. Our bodies need some cholesterol to build cells, make hormones, and help digestion. But problems begin when certain types of cholesterol rise too high. The most dangerous type is low density lipoprotein cholesterol, commonly called LDL or bad cholesterol. When LDL stays high for many years, it sticks to the inner walls of blood vessels. This buildup slowly narrows the arteries and makes them stiff, a condition known as atherosclerosis.
Around 39% of adults worldwide live with raised cholesterol levels. Many don’t even know it. Many people with high cholesterol do not feel sick at first, which is why it is often called a “silent condition”. Over time, however, it can quietly damage the heart and brain. Blocked arteries can lead to heart attacks, strokes, chest pain, shortness of breath, and reduced quality of life. These events can limit daily activities, shorten life expectancy, and place a heavy burden on families and health systems.
Because of these risks, doctors and researchers strongly recommend lowering LDL cholesterol, especially in people who already have heart disease or are at high risk. Lower LDL levels slow plaque buildup and reduce the chance of dangerous blood clots. The main treatment options today include lifestyle changes such as healthier diets, exercise, and quitting smoking, along with medications. The most commonly used medicines are statins, which reduce how much cholesterol the liver makes. Other drugs, like ezetimibe and injectable PCSK9 inhibitors, are added when statins alone are not enough. Still, many patients struggle to reach target LDL levels even with these treatments. This ongoing challenge is what led scientists to develop new cholesterol lowering medicines, including a pill called enlicitide.
Enlicitide is an experimental oral medication designed to lower LDL cholesterol by blocking a protein known as PCSK9. This protein plays an important role in controlling how the liver removes LDL cholesterol from the blood. When PCSK9 is active, it reduces the liver’s ability to clear LDL. By blocking PCSK9, enlicitide helps the liver remove more bad cholesterol from circulation. What makes enlicitide especially notable is that it works through a pathway similar to injectable PCSK9 inhibitors, but it comes in pill form and is taken once daily.
In early February 2026, results from a large phase 3 clinical trial testing enlicitide were published. The study was called CORALreef Lipids. It was one of the largest trials ever conducted for an oral PCSK9 inhibitor. The research took place at 168 medical centers across 14 countries and included 2,909 adult participants. All participants were either living with atherosclerotic cardiovascular disease or were at high risk for having their first major heart related event. Most were already taking standard cholesterol lowering treatments, including statins, before joining the study. Despite this, their LDL cholesterol levels remained higher than recommended. On average, participants were about 63 years old, and nearly 39 percent were women. Their average LDL cholesterol level at the start of the trial was around 96 milligrams per deciliter. The trial was carefully designed to ensure reliable results. It was randomized, double blind, and placebo controlled. Participants were randomly assigned to receive either enlicitide or a placebo pill that looked the same but contained no active medicine. About two thirds of participants received enlicitide at a dose of 20 milligrams once daily, while one third received the placebo. Everyone continued their usual cholesterol medications during the study.
The main goal of the trial was to measure how much LDL cholesterol changed after 24 weeks of treatment. When researchers analyzed the results, they found a clear difference between the two groups. People who took enlicitide experienced an average LDL cholesterol reduction of about 57 percent from their starting level. In contrast, people who took the placebo saw their LDL cholesterol increase slightly by about 3 percent. To understand the difference between the two groups, researchers compared these changes directly. When a 57 percent decrease is compared with a 3 percent increase, the overall difference between the groups comes out to roughly 56 percentage points. This explains why the reported between group difference was about a 56 percent reduction. This result was statistically significant, meaning it was extremely unlikely to have occurred by chance.
The benefits of enlicitide did not stop with LDL cholesterol alone. Other harmful blood lipids also decreased. Non HDL cholesterol levels dropped. Apolipoprotein B, which reflects the number of cholesterol carrying particles in the blood, was reduced. Levels of lipoprotein(a), a cholesterol type linked to inherited heart disease risk, also fell. These improvements were seen at 24 weeks and remained stable through 52 weeks of treatment. Because of these strong effects, many participants reached recommended cholesterol goals. By week 24, a large proportion of people taking enlicitide achieved LDL levels below 70 milligrams per deciliter along with at least a 50 percent reduction from their baseline levels. These targets are commonly recommended for patients at very high cardiovascular risk.
Safety was closely monitored throughout the study. Over one year, the overall number of side effects was similar between the enlicitide and placebo groups. Serious adverse events occurred at similar rates as well. This suggests that enlicitide was generally well tolerated during the trial period. However, researchers emphasized that longer studies are still needed to fully understand long term safety and detect rare side effects. It is important to note what the study did not measure. The CORALreef Lipids trial focused on cholesterol levels, not on actual heart attacks or strokes. While decades of research show that lowering LDL cholesterol reduces cardiovascular risk, this trial did not directly test whether enlicitide lowers the number of heart related events. Large outcome trials are currently underway to answer that question.
From a broader health perspective, these findings are significant. High LDL cholesterol remains one of the leading causes of heart disease worldwide. Many patients do not reach cholesterol goals with existing therapies alone. A once daily pill that produces large LDL reductions could make treatment easier and more acceptable, especially for people who prefer not to use injections. At the same time, medical guideline organizations such as the American Heart Association and the American College of Cardiology typically wait for strong evidence showing fewer heart attacks and strokes before recommending new treatments widely. Until those outcome data are available, doctors are likely to use enlicitide cautiously.
In conclusion, the CORALreef Lipids phase 3 trial showed that enlicitide, an oral PCSK9 inhibitor, can produce large and sustained reductions in LDL cholesterol and other harmful lipids in high risk adults already on standard therapy. The safety profile over one year was similar to placebo. Whether these powerful cholesterol lowering effects translate into fewer heart attacks and strokes will be determined by ongoing outcome trials.
FAQs on Magic pill to reduce cholesterol
Q: What is LDL cholesterol and why is it called bad cholesterol?
A: LDL cholesterol is called bad cholesterol because high levels can stick to artery walls and form plaque. Over time, this plaque narrows blood vessels and increases the risk of heart attacks and strokes. Lowering LDL cholesterol helps protect the heart and brain.
Q: Why do doctors want patients to lower cholesterol levels?
A: Doctors recommend lowering cholesterol because high LDL is a major cause of heart disease worldwide. Lower cholesterol slows artery damage and reduces the chance of serious events like heart attacks. This is especially important for people who already have heart disease or are at high risk.
Q: What is enlicitide and how does it work?
A: Enlicitide is an experimental oral medicine designed to lower LDL cholesterol. It works by blocking a protein called PCSK9, which helps the liver remove bad cholesterol from the blood. Unlike older PCSK9 treatments, enlicitide is taken as a once daily pill.
Q: How effective is enlicitide at lowering cholesterol?
A: In a large phase 3 clinical trial, enlicitide lowered LDL cholesterol by about 57 percent after 24 weeks. People who took a placebo pill saw a small increase in LDL instead. This shows enlicitide produced a much stronger cholesterol lowering effect than no treatment.
Q: How is enlicitide different from statins?
A: Statins reduce the amount of cholesterol the liver makes, while enlicitide helps the liver remove LDL cholesterol from the blood. Many patients already take statins but still have high LDL levels. Enlicitide is designed to be added to standard therapy when statins alone are not enough.
Q: Is enlicitide better than injectable PCSK9 inhibitors?
A: Enlicitide works through a similar pathway as injectable PCSK9 inhibitors and shows comparable LDL cholesterol reductions. The main difference is that enlicitide is taken by mouth rather than by injection. Whether one option is better depends on patient preference, safety data, and future outcome results.
Q: Is enlicitide safe based on current studies?
A: In the CORALreef Lipids trial, side effects and serious adverse events were similar between enlicitide and placebo over one year. This suggests the pill was generally well tolerated in the study population. Longer and larger studies are still needed to confirm long term safety.
Q: Does lowering cholesterol with enlicitide prevent heart attacks and strokes?
A: The published trial measured cholesterol levels, not heart attacks or strokes. While past research shows that lowering LDL reduces heart risk, this specific benefit has not yet been proven for enlicitide. Ongoing outcome trials are designed to answer this question.
Q: When could enlicitide become available for patients?
A: Enlicitide is still under clinical evaluation and has not yet received full regulatory approval. Approval depends on additional safety reviews and results from outcome trials. Regulatory agencies usually require strong evidence before allowing widespread use.
External Sources:
- Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, Kourpanidis S, Lepor NE, Tsukamoto K, Mendizabal G, Nunez J. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. New England Journal of Medicine. 2026 Feb 5;394(6):529-39. Doi: 10.1056/NEJMoa2511002.
- Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ES, Froman S, Mendizabal G, Wang F. Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia: a randomized clinical trial. Jama. 2026 Jan 13;335(2):129-39. Doi: 10.1001/jama.2025.20620.
- The University of Texas Southwestern Medical Center. Experimental pill dramatically reduces ‘bad’ cholesterol. News Release. February 04, 2026. Available from: https://www.utsouthwestern.edu/newsroom/articles/year-2026/feb-experimental-pill-bad-cholesterol.html
Disclaimer:
Some aspects of the webpage preparation workflow may be informed or enhanced through the use of artificial intelligence technologies. While every effort is made to ensure accuracy and clarity, readers are encouraged to consult primary sources for verification. External links are provided for convenience, and Honores does not endorse, control, or assume responsibility for their content or for any outcomes resulting from their use. The author declares no conflicts of interest in relation to the external links included. Neither the author nor the website has received any financial support, sponsorship, or external funding. Photo by Leeloo The First by pexels.com
